Staburo GmbH
Industry / private company
Location:
München,
Germany (DE)
ISNI: -
Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH (2025)
Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Blattner SM, Gan G, Qiang D, et al.
Journal article
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers (2024)
Tian X, Esmaeili H, Minich D, Seitz F, Roessner PM, Wind S, Grempler R, et al.
Journal article
Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis (2023)
Koop K, Enderle K, Hillmann M, Ruspeckhofer L, Vieth M, Sturm G, Trajanoski Z, et al.
Journal article
Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer (2019)
Wiesmüller F, Kopke J, Aust D, Roy J, Dahl A, Pilarsky C, Grützmann R
Journal article